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1658Nasal Epithelial Cells of Donor Origin after Allogeneic
Hematopoietic Cell Transplantation are Generated
at a Faster Rate in the First 3 Months Compared
with Later Posttransplantation
Faisal M. Khan,1,2 Sarah Sy,1 Polly Louie,3 Megan Smith,4 Judy Chernos,4 Noureddine Berka,2
Gary D. Sinclair,2 Victor Lewis,5 James A. Russell,3 Jan Storek1,3Detection of donor-type epithelial cells (ECs) after allogeneic hematopoietic cell transplantation (allo-HCT)
using XY chromosome fluorescein in situ hybridization (FISH) has suggested that hematopoietic stem cells
carry a degree of developmental plasticity. This is controversial, given artifacts of XY-based detection and the
possibility of hematopoietic–nonhematopoietic cell fusion. Moreover, the kinetics of donor-type ECs (quan-
tity at different time points after transplant) is unknown. Here, we document unequivocally the existence of
donor-type ECs using a method obviating the artifacts of XY-FISH and study their kinetics. Nasal scrapings
and blood specimens were collected from 60 allo-HCT survivors between 7 days and 22 years posttransplan-
tation. DNA extracted from laser-captured nasal ECs (ie, CK1CD452 cells) and blood leukocytes was poly-
merase chain reaction–amplified for a panel of 16 short tandem repeat markers. The median percentage of
donor-type ECs (among nasal ECs) was 0% on day 7 posttransplantation, 2.8% at 3 months posttransplanta-
tion, and 8.5% at 12-22 years posttransplantation. Cell fusion was ruled out by FISH analysis for two auto-
somes.We conclude that donor-type nasal ECs exist after HCT, and that their percentage rises rapidly in the
first 3 months posttransplantation and more slowly thereafter.
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Chimerism, CytokeratinINTRODUCTION
Theclassical dogmaof stemcell hierarchy, according
to which the property of pluripotency is restricted to the
embryonic stem cells, has recently been challenged by
studies reporting thepresenceofdonor-typenonhemato-
poietic cells after human allogeneic hematopoietic cell
transplantation (allo-HCT) (reviewed by Spyridonidis
et al. [1]).There is increasing evidence that adult hemato-
poietic stemcells (HSCs) candifferentiate intononhema-
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6/j.bbmt.2010.07.012in normal embryogenesis originate from the ectoderm
or endoderm) [1,2]. Using XY chromosome–based
detection methods, donor-derived nonhematopoietic
cells have been documented in the lungs [3], skin [4], in-
testine [5], liver [6], brain [7], conjunctiva [8], endome-
trium [9], and buccal mucosa [10] of female recipients
of HSC grafts from male donors. Donor-type epithelial
cells (ECs) have been typically identified as Y chromo-
some–containing cells expressing an epithelial lineage
marker (eg, cytokeratin [CK]) andnot expressing a hema-
topoietic lineage marker (eg, CD45). The presumed
transdifferentiation of HSCs may be a repair response
to graft-versus-host disease (GVHD)-induced epithelial
tissue injury [4], although donor-derived ECs also
have been reported in patients without a history of
GVHD [6,10].
Despite the evidences, however, some investigators
consider transdifferentiation or even the existence of
donor-derived ECs contentious (reviewed by Bianchi
and Fisk [11]). Initial skepticism involved methodolog-
ical limitations (eg, assigning Y chromosome to ECs
when in fact it should have been assigned to an
intraepithelial lymphocyte). These limitations were sig-
nificantly addressed in later reports [12]. However, the
Biol Blood Marrow Transplant 16:1658-1664, 2010 1659Donor-Type Nasal Epithelial Cells in Allo-HCT Recipientsprimary reason for the persistent skepticism is fetoma-
ternal chimerism [11]; male fetal cells have been identi-
fied in 48% of healthy parous women [13] as long as 27
years after their last pregnancy with a male offspring
[14].Moreover, the presence of fetomaternal chimerism
results not only from successful pregnancies, but also
from abortions/miscarriages [11]. In addition, the
ability of HSCs to transdifferentiate into ECs has been
repudiated by investigators claiming that the fusion of
donor hematopoietic cells with recipient ECs is the rea-
son for the detection of seemingly donor-derived ECs
[9,15]. Thus, it seems appropriate to reassess whether
donor-type ECs in HCT recipients truly exist, using
a method that is not based on Y chromosome detection
and ruling out cell fusion.
Finally, assuming that the transdifferentiation of
donor-type ECs is in fact real, its kinetics remain un-
known.Using amethod that circumvents the limitations
of Y chromosome–based donor–recipient distinction,
we set out to determine whether donor-type ECs are
truly present in the nasal mucosa (an organ not typically
involved inGVHD) and, if so, tomeasure their quantity
at different posttransplantation time points.METHODS
Subjects and Specimen Collection
A total of 60 subjects were accrued for the study,
which includes both short-term (7-98 days; n 5 32)
and long-term (6-22 years; n5 28) survivors of myeloa-Table 1. Demographic and Clinical Information
Characteristic Short-Term Surv
n 32
Time after transplantation, days Median, 56 days; range, 7-98
Sex Male, n 5 14; female, n 5 1
Age at transplantation, years Median, 53 years; range, 19-
Age at the time of sample collection, years Median, 52 years; range, 20-
Graft source PBSCs, n 5 30; cord blood,
Disease AML, n 5 11; CML/CMML,
n 5 5; CLL/lymphoma, n
Donor type* Related, n 5 16; unrelated,
Conditioning† Flu + Bu + TBI, n 5 18; Flu
n 5 13; VP16 + TBI, n 5
GVHD prophylaxis CsA‡ + MTX§ + ATG¶, n 5
Acute GVHD Yes, 13; no, 19
Chronic GVHDk NA
NA indicates not applicable; AML, acute myelogenous leukemia; ALL, acute lym
lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma
chronic myelomonocytic leukemia; MF, myelofibrosis; Flu, fludarabine; Bu, b
cyclosporine A; MTX, methotrexate; ATG, antithymocyte globulin.
*Both related and unrelated donors were typically HLA-matched. This was
survivors and as allele-matched for HLA-A, -B, -C, -DRB1, and -DQB1 for the
†Myeloablative in all subjects, except possibly the one subject with severe apl
‡Administered for the first 3-6 months posttransplantation, longer in cases o
§Administered on days 1, 3, 6, and 11.
¶Administered on days -2, -1 and 0.
kAt any time between transplantation and sample collection. In most subjectsblative allo-HCT. Written informed consent was ob-
tained from each subject. The University of Calgary’s
Ethics Committee approved the study design. The sub-
jects’ demographic and clinical data are summarized in
Table 1.
Both peripheral blood and nasal scrapings were
collected at approximately 1 week, 1 month, 2 months,
3months, 6-10 years, or 12-22years posttransplantation.
In most subjects, sampling was done only once; in 5
subjects, samples were collected at multiple time points.
Nasal scrapings were collected by first cleaning the nose
with sterile saline swab and then gently but firmly twirl-
ing a sterile curette (Rhino PRO, Arlington-scientific,
Inc. USA) on the inferior nasal turbinate.Cytospinning, Immunocytochemistry, and Laser
Capture Microscopy
Nasal scraping specimenswere dilutedwith 1%PBS
tomaximize the possibility of obtaining single cells after
cytospinning.Between8 and10cytospin slideswerepre-
pared for each specimen by centrifuging 500 mL of cell
suspension on each slide at 5000 RPM using a Cytospin
Cytocentrifuge. The cytospun nasal cells were then
fixed using xylene. All slides from each individual subject
were then subjected to immunocytometry, except in
10 subjects, for whom one slide each was used for the
detectionof cell fusion.Dual-color immunocytochemis-
try was performed using the enzymes alkaline phospha-
tase and horseradish peroxidase and their substrates,
5-bromo-4-chloro-3’-indolyphosphate p-toluidine saltDistribution and Range
ivors Long-Term Survivors
28
days Median, 10 years; range, 6-22 years
8 Male, n 5 18; female, n 5 10
65 years Median, 42 years; range, 18-59 years
66 years Median, 51 years; range, 31-68 years
n 5 2 Bone marrow, n 5 18; PBSCs, n 5 7
n 5 2; ALL,
5 13; MF, n 5 1
AML, n 5 5; CML, n 5 8; ALL, n 5 7;
CLL/lymphoma, n5 6; MM, n5 1; SAA, n5 1
n 5 16 Related, n 5 21; unrelated, n 5 7
+ Bu,
1
Cy + TBI, n 5 6; Cy + Bu, n 5 8; Cy, n 5 1;
Flu + Bu, n 5 11; VP16 + TBI, n 5 2
32 CsA + MTX, n 5 15; MTX + steroid,
n 5 2; CSA + MTX + ATG, n 5 11
Yes, 10; no, 18
Yes, 18; no, 7
phogenous leukemia; CML, chronic myelogenous leukemia; CLL, chronic
; SAA, severe aplastic anemia; MDS, myelodysplastic syndrome; CMML,
usulfan; Cy, cyclophosphamide; VP16, etoposide; Mel, mephalan; CsA,
defined as antigen-matched for HLA-A, -B and -DR for the long-term
short-term survivors.
astic anemia, who received 200 mg/kg cyclophosphamide.
f chronic GVHD.
, chronic GVHD was inactive at the time of sample collection.
1660 Biol Blood Marrow Transplant 16:1658-1664, 2010F. M. Khan et al.and nitro blue tetrazolium chloride (BCIP-NBT) and
3,30-diaminodbenzidine (DAB) (Lab Vision, Fremont,
CA), respectively, after the cellswere stainedwithmono-
clonal antibody directed against human CKs (clone
AE1/AE3) and CD45/leukocyte common antigens
(LCAs). Both ECs (brown CK1 cells) and leukocytes
(blue CD451 cells) were observed (Figure 1A). After
the cells were hydrated, ECs—defined as large brown
(CK1CD45-) cells clearly separated from small blue
(CD451) cells—were subjected to laser capture micro-
dissection (LCM) using an Arcuturus LaserMicrobeam
System (Arcuturus, San Diego, CA) (Figure 1B). A total
of 35-60ECswere laser-captured from each slide, and at
least 200ECswere used for subsequentDNAextraction.Short Tandem Repeat (STR) Analysis
for Chimerism Evaluation
Laser capture microdissected nasal ECs were col-
lected into the lid of a 0.5-mL reaction tube and
digested in 20 mL of Tris-EDTA buffer containing
proteinase K (20 mg/mL) at 56C for 12 hours. After
denaturation at 100C for 10 minutes, the DNA was
used for individual polymerase chain reaction (PCR)
runs. DNA from blood leukocytes was extracted using
theQiagenQIAampDNAMicro Kit (Qiagen,Hilden,
Germany) and denatured at 100C for 10 minutes.
DNA was PCR-amplified for a commercial panel
of 15 autosomal microsatellite markers and an XY-
differentiating locus (Identifiler; Applied Biosystems,
Foster City, CA, USA) to quantify chimerism using the
manufacturer’s recommended operating procedures, re-
agents, and PCR conditions. The fluorochrome-labeled
amplicons together with an internal size standard (500-
LIZ;AppliedBiosystems)were size-fractionatedbydena-
turing capillary electrophoresis on an ABI-3130 genetic
analyzer (Applied Biosystems). The allele analysis based
on fluorescent peak height was done by Genemapper
version 2 software (Applied Biosystems) (Figure 1B).
Stutter peaks, dye-associated peaks, blobs, and
spikes were identified and excluded from the analysis.
Pretransplantation DNA from donor and recipient
were used to determine the informative markers (one
with a distinct allelic profile for donor and recipient).
Fluorescent measurements were used to estimate the
quantity ofDNA at an allele of the informativemicrosa-
tellitemarker in the posttransplantation specimen. This
DNA estimate served as the basis for computing the
relative proportions of the donor and recipient compo-
nents (Figure 1B). Donor chimerism percentage for
each runwasdeterminedbycalculating themeanchime-
rism for all informative microsatellite markers using
ChimerTrack software [16]. Each DNA sample was
analyzed in 3 independent PCR runs, followed by the
electrophoretic run. Other stringent parameters, in-
cluding DNA measurement error, were used to gauge
the performance of each microsatellite marker [17].Our calibration experiments showed an assay sensitivity
of 0.1% for detecting the minor allele when we used
electrophoretic modifications, such as a 50-second in-
jection time, as described previously [18].
In control experiments, we mixed nasal scrapings
from healthy individual A with blood buffy coat cells
from healthy individual B and treated this artificially
mixed specimen as a nasal specimen from a transplant
recipient (ie, staining for CK and CD45, LCM of
CK1CD45- cells, DNA extraction, and chimerism
analysis using STRs). In a set of 5 experiments, we de-
tected a maximum of 0.5%DNA of individual B in the
laser-captured ECs from individual A. Thus, all results
of nasal EC chimerism in transplant recipients are re-
ported as corrected percentage of donor cells (0.5%
subtracted from the mean percent donor chimerism
obtained after 3 runs, whenever the donor chimerism
was .0.5%).
Circulating leukocytes were of.92% donor origin
in all subjects studied at 2months or later posttransplan-
tation. In subjects studied earlier after transplantation,
the median percentage of donor-type leukocytes (of to-
tal leukocytes) was 58% (range, 52%-68%) on days 7-8
and 79% (range, 72%-90%) on days 28-32.
Assessment of Hematopoietic–EC Fusion
To examine whether the detection of donor-type
nasal ECs is a result of EC fusion with a hematopoietic
cell, an additional cytospin slide from 10 subjects was
analyzed by combining CK staining with fluorescein in
situ hybridization (FISH) for two autosomal chromo-
somes (chromosomes 7 and 14) and examined for the
number of chromosome signals present in all CK1 cells
(Supplementary Figure 1). In case of cell fusion, some
CK1 cells would be expected to have 4 signals (instead
of the 2 seen in diploid cells) for each chromosome.
Two chromosomeswere used for FISH analysis because
fusionmight lead to the loss of some chromosomes, and
thus thedetectionof twochromosomes shouldminimize
the chance of false-negative results.
Statistical Analysis
Allo-HCT recipients were grouped based on the
time after transplantation (day 7-8, day 28-32, day 54-
62, day 84-98, 6-10 years, and 12-22 years). The 6-10
year group was further subdivided into a subgroup of pe-
ripheral blood stem cell transplantation (PBSCT) recipi-
ents and bonemarrow transplantation (BMT) recipients.
All subjects studied between days 7 and 98 posttransplan-
tation received PBSCT, and all those studied at 12-22
years posttransplantation underwent BMT. The signifi-
cance of the difference in the percentages of donor-
type nasal ECs collected at different time points after
HCT was tested using the Mann-Whitney-Wilcoxon
rank-sum test. A P value of .05 (two-tailed) or less was
considered significant.
Figure 1. EC chimerism analysis. (A) Dual-color immunocytochemistry performed after staining cytospun nasal mucosal cells with monoclonal anti-
bodies directed against human CKs and CD45. Brown cells represent CK1 ECs; blue cells, and CD451 leukocytes. Red arrows indicate single
CK1CD45- ECs that were used mainly for LCM. (B) A laser-captured single EC (CK1CD45- cell). (C) An example of STR-based chimerism analysis.
PCR-amplified DNA from the following specimens was studied: (i) recipient PBMCs pretransplantation, (ii) donor peripheral blood mononuclear cells
(PBMCs) pretransplantation, (iii) recipient PBMCs posttransplantation (7 years posttransplantation in this example) and (iv) Laser-captured CK1CD45-
nasal ECs from a recipient at 7 years posttransplantation. The allelic profile is shown at 4 microsatellites (from left to right): D8S1179, D21S11 D7S820,
and CSF1PO. The posttransplantation blood specimen showed 100% donor chimerism, and posttransplantation nasal ECs showed 8.2% donor chime-
rism in this example. An asterisk denotes donor-specific peaks detected in the CK1CD45- nasal ECs from the recipient posttransplantation.
Biol Blood Marrow Transplant 16:1658-1664, 2010 1661Donor-Type Nasal Epithelial Cells in Allo-HCT RecipientsRESULTS
Unequivocal Detection of Donor-Type Nasal
ECs
Donor-typeECsweredetected in60of68nasalmu-
cosal specimens from allo-HCT recipients (88% of
the total specimens analyzed) with the LCM/STR
method that precludes artifacts ofYchromosome–baseddetection. To examine whether donor-type ECs de-
tected by the LCM/STR method resulted from cell fu-
sion, we used a combination of CK staining with FISH
for two autosomal chromosomes (chromosomes 7 and
14) and examined the number of chromosome signals
present in all CK1 cells (250-300 cells per specimen)
in nasal specimens from 10 allo-HCT recipients. Cells
generated by cell fusion in vivo have been reported to
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Figure 2. Percentage of donor-type nasal ECs collected from early (day
7-98) and late (6-22 years) posttransplantation recipients. Shown is the
percentage of donor-type ECs detected in the nasal specimens among
the following group of allo-HCT recipients (circles): day 7-8 (median,
7 days), day 28-32 (median, 30 days), day 56-62 (median, 56 days), day
84-98 (median, 88 days), 6-10 years who underwent PBSCT (median,
9 years) and 6-10 years (median, 9 years) and.10-22 years who under-
went BMT (median, 17 years). The horizontal bars represent the median
values. The P value for significance of the difference between two groups
of subjects is shown in the space between the groups. *The P value was
not calculated between day 7-8 (median, 7 days) and day 28-32 (median,
30 days), because none of the day 7-8 posttransplantation recipients
showed donor-type ECs. The P value of .05 is an arbitrary value indicat-
ing a significant increase in donor-type ECs in day 28-32 posttransplan-
tation recipients.
1662 Biol Blood Marrow Transplant 16:1658-1664, 2010F. M. Khan et al.form polyploid cells known as heterokaryons [19]. If
seemingly donor-type ECs were generated by cell fu-
sion, then probes for a single somatic chromosome
would target at least 4 chromosomes within the nucleus
of those cells. We did not find any ECs with more than
two signals for each chromosome in the nuclei of CK1
cells (Supplementary Figure 1). This indicates that the
donor-type ECs were truly of donor origin.Faster Generation of Donor-Type ECs Early
Postransplantation Compared with Late
Posttransplantation
As shown in Figure 2, the median percentages of
donor-type nasal ECs (of all nasal ECs) were 0% on
day 7, 0.6% on days 28-32, 2.0% on days 56-62,
2.8% on days 84-98, and 5.1% at 6-10 years (median,
9 years) after PBSCT, and 7.0% at 6-10 years (median,
9 years) and 8.5%at 12-22 years (median, 17 years) after
BMT. The main determinant of the percentage of
donor ECs was the time after transplantation; note
the significant differences between most adjacent time
points in Figure 2. The percentage at 6-10 years was
slightly, but statistically significantly, higher post-
BMT compared with post-PBSCT, perhaps because
transferred marrow stromal cells might facilitate trans-
differentiation [20]. Other clinical/demographic factors
did not appear to play a role; exploratory analyses found
no association between the percentage of donor-typenasal ECs and recipient age at the time of transplanta-
tion or the time of sampling, sex, donor type (HLA-
matched sibling vs unrelated), underlying disease
(myeloid vs lymphoid), type of preparative regimen
(with vswithout total body irradiation [TBI]), or history
of acute GVHD (grade 0-I vs II-IV). The percentage of
donor-type ECs increased rapidly early after transplan-
tation; no donor-type ECs were found in the subjects
evaluated on day 7, whereas 50% of the subjects studied
at days 28-32 had detectable donor-type ECs (median,
0.6%), and 100% of the subjects studied between day
56 and day 98 had detectable donor-type ECs (median,
2.0% on days 56-62 and 2.8% on days 84-98). The ma-
jority of the subjects who underwent nasal mucosa sam-
pling multiple time points early after transplantation
had evidence of a rapidly increasing percentage of
donor-type ECs (Figure 3). The increase was slower af-
ter 3 months posttransplantation compared with that
seen during the first 3 months after transplantation
(Figure 2). Specifically, the rate of increase between 1
and 3 months posttransplantation was 2.2% (2.8%-
0.6%) per 2 months (ie, 13.20% per year), that between
3 months and 9 years was 2.3% (5.1%-2.8%) per 8.75
years (ie, 0.26% per year), and that between 9 and 17
years was 1.5% (8.5%-7.0%) per 8 years (ie, 0.19%
per year).DISCUSSION
The present study has demonstrated the presence of
donor-type ECs in allo-HCT recipients using a method
that obviates the artifacts of XY-FISH. It also has shown
that the donor-typeECs are primarily generated early af-
ter transplantation. Early reports suggesting that human
allo-HCT leads to chimerism of not onlyHSCs, but also
ECs, were challenged in 1999, whenEndler et al. [21] as-
sumed that the donor DNA found in recipient buccal
ECs resulted from hematopoietic ‘‘contaminants’’
among ECs. Nevertheless, subsequent, more carefully
conducted studies reported the existence of donor-type
ECs [6,22-24]. Spyridonidis et al. [12] and Murata et al.
[4] used stringent methods, including hematopoietic
markers and 3-dimensional histological analysis, to rule
outhematopoietic contaminants.But, despite technolog-
ical advances, no studywas able to preclude the problems
associated with Y chromosome–based detection of
donor-type cells, including fetomaternal chimerism
[11], blood transfusion from amale donor [25], quantita-
tive inaccuracy of FISH in detecting Y chromosome–
containing cells [26], and loss of Y chromosome,
especially in elderly donors [27]. Perhaps for this latter
reason, we found higher percentages of donor-type
ECs compared with those reported by studies that used
a combination of CK and CD45 staining with Y-FISH
using confocal micrososcopy. Our relatively high per-
centage of ECs cannot be from hematopoietic
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Figure 3. Percentage of donor-type ECs in the nasal epithelial speci-
mens collected from 5 allo-HCTrecipients at different time points after
transplantation. Shown are the percentages of donor-type ECs detected
in the nasal specimens collected from recipient A on days 8, 31, and 60
posttransplantation, from recipient B on days 7 and 32 posttransplanta-
tion, from recipient C on days 7 and 56 posttransplantation, from recip-
ient D on days 7, 28, 62, and 95 posttransplantation, and from recipient E
on days 56 and 94 posttransplantation.
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CD45) to rule out infiltrating/adhering leukocytes.
Moreover, we performed LCM of only single or paired
CK1CD45- cells, clearly separated from CD451 cells,
to discount the possibility of leukocyte contamination.
In addition, our relatively high percentage of ECs cannot
be due to the quantitative inaccuracy of the STR tech-
nique, because we used highly stringent parameters, in-
cluding average donor DNA percentage detected by 16
STR markers, measurement error to eliminate an aber-
rant marker profile [17], and the mean chimerism per-
centage from 3 independent PCR and electrophoresis
runs. The 16 STR marker panel is used routinely at our
center for clinical engraftment monitoring, and our lab-
oratory has a 100% proficiency testing record in the
American Society for Histocompatibility and Immuno-
genetics annual proficiency testing. Another reason for
our relativelyhighpercentageofECscouldbe thedisper-
sion of genetic material from leukocytes on slides during
cytospinning, which might have been laser-captured
along with CK1CD45- ECs. This is unlikely, however,
given the results of our controlmixing experiments of na-
sal cells from individual A with leukocytes from individ-
ual B (seeMethods), and because no chromosome signals
outside of nuclei were detected on any of the 10 cytospin
slides stained by FISH for chromosomes 7 and 14
(Supplementary Figure 1).
Themost salient findingsof the present study are the
kinetics of EC chimerism. The rapid increase early after
transplantation suggests that the early posttransplanta-
tion state (mucosal repair from conditioning-induced
damage?) facilitates theHCS toEC transdifferentiation.
The significant increase in donor-type ECs between 3
months and 9 years post-PBSCT and the increasing
trend between 9 and 17 years post-BMT suggest that
the transdifferentiation is ongoing even late posttrans-plantation. Two earlier reports noted a similar kinetic
trend for ECs of the buccalmucosa [10] and gastrointes-
tinal tract [23]; however, the numbers of subjects were
too small to allow conclusive statements on kinetics.
Regarding thefirstmonthposttransplantation,we found
donor-type nasal ECs in no subjects studied at 1 week
after transplantation and in 50% of subjects studied at
1 month posttransplantation, whereas other investiga-
tors found donor-type ECs in skin or colon already at
7-15 days posttransplantation [10]. This discrepancy
could be related to the relatively long turnover time of
nasal epithelium (20-80 days [28]) compared with 7
days for skin and 5 days for colon [10], or could result
from the limited sensitivity of our assay.
The present study has some limitations. First, we
were not able to detect\0.5% of donor-type ECs be-
cause of the limited sensitivity of the STR-based analy-
sis, as well as the backgroundwe found inmixing studies
of nasalmucosal cells.Nevertheless, we detected donor-
type cells in 82%of our allo-HCT recipients, with non-
detection restricted to the very early posttransplantation
period (days 7-32). Second, our ruling out cell fusion as
the possible mechanism of detecting donor-type ECs
might have been incomplete, given that heterokaryons
rarely give rise to two euploid cells by cytoreductive
division [19]. Third, apart from transdifferentiation,
other mechanisms might explain the presence of
donor-type ECs after allo-HCT, such as the transfer
of ECs or their precursors with the HSC graft; we
have found ECs or their precursors in PBSC grafts
(Khan et al, unpublished data, March 2010). Another
possible mechanism underlying donor-type EC detec-
tion is horizontal gene transfer (ie, ECs phagocytosing
DNA from apoptotic hematopoietic cells) [29]. In vitro
experiments using epithelial and T cell lines recently
suggested this mechanism [29], but whether or not the
transfer can occur in vivo is unknown. But even if this
transfer could occur in vivo, our inability to detect
donor-typeECsonday7-8despite the fact that amedian
of 58% leukocytes were of donor origin argues against
horizontal gene transfer as a significant reason for our
detection of donor-type ECs. Finally, it also is impor-
tant to mention that mucosal sampling was done only
once in most cases, and that the kinetics of the EC chi-
merism would have been more conclusive had there
beena smaller timegapbetweenearly and lateposttrans-
plantation survivors, allthough a rapidly increasing
percentage of donor-type ECs was observed in most
subjects who underwent nasal mucosa sampling at mul-
tiple time points early after transplantation.
Overall, our results indicate that donor-type ECs
are present in most allo-HCT recipients, are present
even in organs that typically are not involved with
GVHD, and increase in number rapidly in the first
several months after transplantation and continue to
increase slowly thereafter. In an optimistic scenario,
these findings suggest that allo-HCT could be used
1664 Biol Blood Marrow Transplant 16:1658-1664, 2010F. M. Khan et al.instead of epithelial organ transplantation to treat
epithelial diseases like cystic fibrosis and thereby avoid
the need for life-long pharmacologic immunosuppres-
sion. From this perspective, it will be important to de-
termine what stimulates the generation of donor-type
ECs early after transplantation; the use of that stimulus
might be explored for increasing the amount of donor-
type ECs to a physiologically relevant number. On the
other hand, the presence of donor-type ECs also may
be associated with such posttransplantation problems
as donor-type carcinoma, possibly because of an asso-
ciation between transdifferentiation and malignant
transformation [30].ACKNOWLEDGMENTS
The authors thank the subjects for participating in
research that could not benefit them. This study could
not have been conducted without the dedication of
Lynne Fisk, Judy Wu, Glennis Doiron, Vandana
Singh, and the staff of the Alberta Blood and Marrow
Transplant Program, including inpatient and outpa-
tient nurses andDrs Ahsan Chaudhry,Nancy Zacarias,
Ping Yue, Nizar Bahlis, Chris Brown, Andrew Daly,
Peter Duggan, Michelle Geddes, Lynn Savoie, Doug-
las Stewart, Mona Shafey, Loree Larratt, and Robert
Turner. Funding was provided by the AlbertaHeritage
Foundation for Medical Research, Canada Research
Chair Program, Canada Foundation for Innovation,
and Alberta Cancer Foundation.
Financial disclosure: The authors have no conflicts
of interest to disclose.SUPPLEMENTARY DATA
Supplementary data associated with this article can
be found, in the online version, at doi:10.1016/
j.bbmt.2010.07.012.REFERENCES
1. Spyridonidis A, Mertelsmann R, Finke J. Hematopoietic stem
cell transplantation: more than just hematopoietic? J Cancer
Res Clin Oncol. 2004;130:127-134.
2. Korbling M, Estrov Z. Adult stem cells for tissue repair: a new
therapeutic concept? N Engl J Med. 2003;349:570-582.
3. Suratt BT, Cool CD, Serls AE, et al. Human pulmonary chime-
rism after hematopoietic stem cell transplantation. Am J Respir
Crit Care Med. 2003;168:318-322.
4. Murata H, Janin A, Leboeuf C, et al. Donor-derived cells and
human graft-versus-host disease of the skin. Blood. 2007;109:
2663-2665.
5. Matsumoto T, Okamoto R, Yajima T, et al. Increase of bone
marrow–derived secretory lineage epithelial cells during regenera-
tion in the human intestine.Gastroenterology. 2005;128:1851-1867.
6. Korbling M, Katz RL, Khanna A, et al. Hepatocytes and epithe-
lial cells of donor origin in recipients of peripheral-blood stem
cells. N Engl J Med. 2002;346:738-746.7. Crain BJ, Tran SD, Mezey E. Transplanted human bone marrow
cells generate new brain cells. J Neurol Sci. 2005;233:121-123.
8. Eberwein P, Faber P, Reinhard T, et al. Conjunctival epithelial
cells with donor-derived genome after human haematopoietic
stem cell transplantation. Transplantation. 2009;87:915-918.
9. KorblingM, de LimaMJ, Thomas E, et al. Fusion of circulating
blood cells with solid-organ tissue cells in clinical stem cell
transplants: a potential therapeutic model? Regen Med. 2008;3:
157-164.
10. Metaxas Y, Zeiser R, Schmitt-Graeff A, et al. Human hemato-
poietic cell transplantation results in generation of donor-
derived epithelial cells. Leukemia. 2005;19:1287-1289.
11. Bianchi DW, Fisk NM. Fetomaternal cell trafficking and the
stem cell debate: gender matters. JAMA. 2007;297:1489-1491.
12. Spyridonidis A, Schmitt-Graff A, Tomann T, et al. Epithelial
tissue chimerism after human hematopoietic cell transplantation
is a real phenomenon. Am J Pathol. 2004;164:1147-1155.
13. Adams KM, Lambert NC, Heimfeld S, et al. Male DNA in
female donor apheresis and CD34-enriched products. Blood.
2003;102:3845-3847.
14. BianchiDW, Zickwolf GK,Weil GJ, et al.Male fetal progenitor
cells persist inmaternal blood for as long as 27 years postpartum.
Proc Natl Acad Sci USA. 1996;93:705-708.
15. Wurmser AE,Gage FH. Stem cells: cell fusion causes confusion.
Nature. 2002;416:485-487.
16. Kristt D, Stein J, Yaniv I, et al. InteractiveChimerTrack software
facilitates computation, visual displays and long-term tracking of
chimeric status based on STRs. Leukemia. 2004;18:909-911.
17. Kristt D, Klein T. Reliability of quantitative chimerism results:
assessment of sample performance using novel parameters. Leu-
kemia. 2006;20:1169-1172.
18. Buno I, Nava P, Simon A, et al. A comparison of fluorescent in
situ hybridization andmultiplex short tandem repeat polymerase
chain reaction for quantifying chimerism after stem cell trans-
plantation. Haematologica. 2005;90:1373-1379.
19. Weimann JM, Johansson CB, Trejo A, et al. Stable reprog-
rammed heterokaryons form spontaneously in Purkinje neurons
after bone marrow transplant. Nat Cell Biol. 2003;5:959-966.
20. Pittenger MF, Beck SC, Mackay AM, et al. Multilineage poten-
tial of adult human mesenchymal stem cells. Science. 1999;284:
143-147.
21. Endler G,GreinixH,Winkler K, et al. Genetic fingerprinting in
mouthwashes of patients after allogeneic bone marrow trans-
plantation. Bone Marrow Transplant. 1999;24:95-98.
22. Alison MR, Poulsom R, Jeffery R, et al. Hepatocytes from non-
hepatic adult stem cells [Brief Communications]. Nature. 2000;
406:257.
23. Okamoto R, Yajima T, Yamazaki M, et al. Damaged epithelia
regenerated by bone marrow–derived cells in the human
gastrointestinal tract. Nat Med. 2002;8:1011-1017.
24. TheiseND,NimmakayaluM,Gardner R, et al. Liver from bone
marrow in humans. Hepatology. 2000;32:11-16.
25. Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leuko-
cyte subpopulations in immunocompetent transfusion recipi-
ents: frequent long-term microchimerism in severe trauma
patients. Blood. 1999;93:3127-3139.
26. Koopmans M, Kremer Hovinga IC, Baelde HJ, et al. Endothe-
lial chimerism in transplantation: looking for needles in a hay-
stack. Transplantation. 2006;82:S25-S29.
27. Buno I, Kwon M, Balsalobre P, et al. Heterogeneous loss of the
Y chromosome in leukocyte lineages of donor origin after stem
cell transplantation. Bone Marrow Transplant. 2006;38:463-465.
28. Basbaum C, Jany B. Plasticity in the airway epithelium. Am J
Physiol. 1990;259:L38-L46.
29. Waerhous M. Horizontal gene transfer through apoptotic
goodies confers a novel mechanism of epithelial chimerism after
allogeneic HCT [Abstract]. Biol Blood Marrow Transplant. 2010;
16(Suppl 2):S274.
30. Janin A, Murata H, Leboeuf C, et al. Donor-derived oral
squamous cell carcinoma after allogeneic bone marrow trans-
plantation. Blood. 2009;113:1834-1840.
